ReviewDermatology and therapy2020
Sonidegib: Safety and Efficacy in Treatment of Advanced Basal Cell Carcinoma.
Review in Dermatology and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 52 citations in OpenAlex.
- Pathological Insights into the Limitations of Clinical and Dermoscopic Evaluations in Monitoring Sonidegib Treatment Response for Locally Advanced Basal Cell Carcinoma: A Real-World Study.Dermatology and therapy · 2026Article
- Managing Advanced Basal Cell Carcinoma: A Guide for the Dermatology Clinician.The Journal of clinical and aesthetic dermatology · 2025Review
- In vivo sonic hedgehog pathway antagonism temporarily results in ancestral proto-feather-like structures in the chicken.PLoS biology · 2025Article
- A Sonidegib Experience in the Treatment of Basal Cell Carcinoma with Systemic Lupus Erythematosus: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
- Fabrication and In Vivo Evaluation of In Situ pH-Sensitive Hydrogel of Sonidegib-Invasomes via Intratumoral Delivery for Basal Cell Skin Cancer Management.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Therapeutic Approaches for Non-Melanoma Skin Cancer: Standard of Care and Emerging Modalities.International journal of molecular sciences · 2024Review
- The role of Hedgehog and Notch signaling pathway in cancer.Molecular biomedicine · 2022Review
- Giant basal cell carcinoma of the vulva successfully treated with Sonidegib.Dermatologic therapy · 2022Article
- Non-melanoma skin cancers: physio-pathology and role of lipid delivery systems in new chemotherapeutic treatments.Neoplasia (New York, N.Y.) · 2022Review
- Sonidegib-induced muscle spasms in the treatment of basal cell carcinoma: Strategies to adopt.Dermatologic therapy · 2022Article
- Sonidegib with and Without Adjunctive Treatment for Locally Advanced Basal Cell Carcinomas.The oncologist · 2022Article
- Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: a Retrospective Study.Acta dermato-venereologica · 2022Observational
- Understanding Abnormal SMO-SHH Signaling in Autism Spectrum Disorder: Potential Drug Target and Therapeutic Goals.Cellular and molecular neurobiology · 2022Review
- Sonidegib treatment in patients with locally advanced basal cell carcinoma.Dermatologic therapy · 2022Article
- Vismodegib treatment in advanced basal cell carcinomas: Real-life experience.Dermatologic therapy · 2022Article
- Patidegib in Dermatology: A Current Review.International journal of molecular sciences · 2021Review
- Improving the Antitumor Activity and Bioavailability of Sonidegib for the Treatment of Skin Cancer.Pharmaceutics · 2021Article
- Systemic hedgehog inhibitors to treat locally advanced basal cell carcinomas of the head-neck region: A retrospective study.Dermatologic therapy · 2021Article
- First reported case of concurrent sonidegib and radiotherapy for recurrent, advanced basal cell carcinoma.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2021Article
- Recent Research Progress of Chiral Small Molecular Antitumor-Targeted Drugs Approved by the FDA From 2011 to 2019.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hedgehog inhibitors are promising alternative treatments for patients with advanced basal cell carcinomas. Sonidegib (Odomzo
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.